<DOC>
	<DOCNO>NCT02753062</DOCNO>
	<brief_summary>This open-label , multi-center , prospective , single arm phase 2 trial combination bendamustine rituximab patient PTLD , monomorphic cluster differentiation antigen 20 ( CD20 ) positive DLBCL . The investigator want investigate efficacy safety combination bendamustine rituximab patient previously untreated PTLD , monomorphic CD20 ( + ) diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Bendamustine Plus Subcutaneous Rituximab Patients With Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Monomorphic PTLD comprise 70 % PTLDs diffuse large B-cell lymphoma predominant subtype . However , none trial perform specific population DLBCL type monomorphic PTLD . The investigator select Patients proven , measurable monomorphic PTLD DLBCL solid organ transplantation ( e.g . heart , lung , liver kidney etc. ) . Patients PTLD without Epstein-Barr virus ( EBV ) association , positive CD20 monomorphic DLBCL type . The B-R treatment continue 6 cycle interval 21 day . Patients receive 375 mg/m2 day 1 bendamustine 120 mg/m2 intravenous infusion day 2 3 first cycle . From 2nd 6th cycle , rituximab administer subcutaneously fix dose 1400 mg bendamustine 120 mg/m2 intravenous infusion day 1 follow administration rituximab day 2 . On first day infusion bendamustine cycle , palonosetron 0.25 mg give single intravenous injection 30 minute infusion bendamustine . Pegfilgrastim 6 mg administer single subcutaneous injection 24 48 hour completion chemotherapy cycle . Based relatively good safety profile efficacy bendamustine rituximab ( BR regimen ) , investigator investigate feasibility BR regimen immunocompromised patient DLBCL type monomorphic PTLD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Written inform consent 2 . Histologically confirm adult patient diagnose CD20positive monomorphic PTLD , DLBCL irrespective EBV association 3 . Patients undergone solid organ transplantation ( heart , lung , liver , kidney , pancreas , small intestine transplantation , etc combination organ transplantation mention ) . 4 . No prior treatment PTLD , DLBCL except reduction immunosuppression 5 . At least one measurable lesion ≥ 1.5 cm great transverse diameter spiral CT 6 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 . 7 . Age ≥ 19 8 . Adequate renal function : serum creatinine level &lt; 2.0 mg/dL 9 . Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) , bilirubin &lt; 2 X upper normal value ( &lt; 5 x ULN presence DLBCL involvement liver ) 10 . Adequate hematological function : hemoglobin ≥ 9.0 g/dL absolute neutrophil count ( ANC ) ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma . ( Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment ) . 11 . Life expectancy 6 month 12 . A negative serum urine pregnancy test prior treatment must available pre menopausal woman woman &lt; 1 year onset menopause . 13 . Female patient child bear potential must use effective method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide abstinence ) treatment period 12 month thereafter ; Males must use effective method birth control treatment period 12 month thereafter . 1 . Other subtypes PTLD monomorphic CD20 ( + ) DLBCL 2 . Previous treatment PTLD , DLBCL immunotherapy chemotherapy except shortterm corticosteroid ( duration ≤ 8 day ) inclusion ( Low dose steroid immunosuppressant allow . ) 3. central nervous system ( CNS ) involvement lymphoma evidence spinal cord compression . 4 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin , early gastric cancer carcinoma situ cervix breast untreated prostatic cancer without plan treatment ) unless patient free disease ≥ 3 year 5 . Patients known history HIV HCV seropositivity . 6 . Patients active hepatitis B i. HBsAg positive ii . HBsAg negative , antiHBcAb positive HBVDNA PCR positive patient 7 . Pregnant lactate woman 8 . Men surgically sterile woman childbearing potential employ adequate contraception 9 . Other serious illness medical condition . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month ii . History significant neurological psychiatric disorder include dementia seizure iii . Active , uncontrolled infection require systemic antibiotic therapy serious infection within 14 day study enrollment iv . Other serious medical illness 10 . Known hypersensitivity study drug ingredient 11 . Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>